Clinical Value of the Measurable Residual Disease Status within the ELN2017 Risk Groups in AML Patients undergoing Allogeneic Stem Cell Transplantation.

Here we evaluated the clinical value of measurable residual disease (MRD) assessment within the genetic context in acute myeloid leukemia (AML) patients. The ability of MRD to identify patients at higher risk of relapse after an allogeneic hematopoietic stem cell transplantation (HSCT) was reduced in adverse risk compared to favorable or intermediate risk patients. Furthermore, MRD-negative patients in the adverse risk group experienced relapses much earlier compared to the other risk groups. The clinical value of MRD assessment seems to depend on the genetic context, which needs to be considered for treatment or surveillance aspects following HSCT. This article is protected by copyright. All rights reserved.